Clinical Trial Update: Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study of carboplatin, pemetrexed, and panitumumab in advanced non-squamous KRAS wild-type non-small cell lung cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Panitumumab (panitumumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-04-15